ConductScience.org, home

Paper35530735

Economic Burden and Quality of Life of Hepatocellular Carcinoma in Greater China: A Systematic Review.

Zou H and 8 others. Front Public Health, 2022. Cited by 54 papers, by iCite.

Cite this record

ConductScience Library. Economic Burden and Quality of Life of Hepatocellular Carcinoma in Greater China: A Systematic Review. Papers, record 35530735. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35530735

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Economic Burden and Quality of Life of Hepatocellular Carcinoma in Greater China: A Systematic Review.
PubMed
Journal
Front Public Health
PubMed
Year
2022
PubMed
Publication types
Systematic Review, Research Support, Non-U.S. Gov't, Journal Article
PubMed
Citations, by iCite
54
iCite
Relative citation ratio, by iCite
4.3
iCite
Revised in PubMed
2022-07-16
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zou HHuimin
2Li MMeng
3Lei QQing
4Luo ZZejun
5Xue YYan
6Yao DDongning
7Lai YYunfeng
8Ung COLCarolina Oi Lam
9Hu HHao

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, HepatocellularMajor topic
Liver NeoplasmsMajor topic
Adult
China
Financial Stress
Humans
Quality of Life

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT06419478Postoperative Symptoms in Chinese Liver Cancer Patients: Network AnalysisResults

Source ClinicalTrials.gov

Download CSV of trials

References60

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
111980994Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire.J Clin Oncol2002https://conductscience.org/library/papers/11980994PubMed
230776212Humanistic and economic burden of hepatocellular carcinoma: systematic literature review.Am J Manag Care2019https://conductscience.org/library/papers/30776212PubMed
328052758Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data.BMC Cancer2017https://conductscience.org/library/papers/28052758PubMed
418471552Diagnosis and treatment of hepatocellular carcinoma.Gastroenterology2008https://conductscience.org/library/papers/18471552PubMed
531768732Impact of the disclosure of diagnosis on posttraumatic stress and growth and quality of life in Chinese patients with hepatocellular carcinoma.Support Care Cancer2020https://conductscience.org/library/papers/31768732PubMed
626054909Advances in targeted therapies for hepatocellular carcinoma in the genomic era.Nat Rev Clin Oncol2015https://conductscience.org/library/papers/26054909PubMed
726567897Impact of disclosure of diagnosis and patient autonomy on quality of life and illness perceptions in Chinese patients with liver cancer.Psychooncology2016https://conductscience.org/library/papers/26567897PubMed
812187175Estimating health care costs related to cancer treatment from SEER-Medicare data.Med Care2002https://conductscience.org/library/papers/12187175PubMed
930486324Treatment and Cost of Hepatocellular Carcinoma: A Population-Based Cohort Study in Taiwan.Int J Environ Res Public Health2018https://conductscience.org/library/papers/30486324PubMed
1015042359Randomized controlled trial of screening for hepatocellular carcinoma.J Cancer Res Clin Oncol2004https://conductscience.org/library/papers/15042359PubMed
1127281033The Role of Age in Change in Unmet Supportive Care Needs in Hepatocellular Carcinoma Patients During Transition From Hospital to Home.Cancer Nurs2017https://conductscience.org/library/papers/27281033PubMed
1224764650Hepatocellular carcinoma review: current treatment, and evidence-based medicine.World J Gastroenterol2014https://conductscience.org/library/papers/24764650PubMed
1322519878Mini-nutritional assessment predicts functional status and quality of life of patients with hepatocellular carcinoma in Taiwan.Nutr Cancer2012https://conductscience.org/library/papers/22519878PubMed
1431040713Correlations of health-related quality of life with serum inflammatory indicators IL-8 and mIBI in patients with hepatocellular carcinoma.Cancer Manag Res2019https://conductscience.org/library/papers/31040713PubMed
1518405598[Evaluation of Chinese version of the Functional Assessment of Cancer Therapy-Hepatobiliary questionnaire].Zhong Xi Yi Jie He Xue Bao2008https://conductscience.org/library/papers/18405598PubMed
1619622511Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.Ann Intern Med2009https://conductscience.org/library/papers/19622511PubMed
172509745Clinical economics. A guide to the economic analysis of clinical practices.JAMA1989https://conductscience.org/library/papers/2509745PubMed
1820304101Health-related quality of life in patients with hepatocellular carcinoma: a systematic review.Clin Gastroenterol Hepatol2010https://conductscience.org/library/papers/20304101PubMed
1919622552The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.BMJ2009https://conductscience.org/library/papers/19622552PubMed
2019302335Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden.J Viral Hepat2009https://conductscience.org/library/papers/19302335PubMed

See all 60 referencesDownload CSV of references

Cited by39

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 54 citations.

PMIDTitleJournalYearIn PapersSource
42959463Patient-reported financial toxicity among patients with liver cancer: a systematic review and meta-analysis.Front Public Health2026https://conductscience.org/library/papers/42959463PubMed
41951898EcoRxAgent: an AI agent for generating economically substitutable prescriptions.NPJ Digit Med2026https://conductscience.org/library/papers/41951898PubMed
41827595Breathing Exercise for Chronic Pain Management in Breast Cancer Survivors: Feasibility Outcomes and Qualitative Insights from a Pilot Randomised Controlled Trial.Healthcare (Basel)2026https://conductscience.org/library/papers/41827595PubMed
41815170Construction and validation of a prognostic model associated with chromatin remodeling in hepatocellular carcinoma.Transl Cancer Res2026https://conductscience.org/library/papers/41815170PubMed
41640958Evaluation of the impact of an interdisciplinary team scheduling model on psychological outcomes in patients with decompensated cirrhosis.World J Hepatol2026https://conductscience.org/library/papers/41640958PubMed
41595249Two-Stage Microwave Hyperthermia Using Magnetic Nanoparticles for Optimal Chemotherapy Activation in Liver Cancer: Concept and Preliminary Tests on Wistar Rat Model.Cancers (Basel)2026https://conductscience.org/library/papers/41595249PubMed
41411278Efficacy and safety of Atezolizumab plus Bevacizumab and Lenvatinib as first-line systemic therapies for hepatocellular carcinoma: A real-world study.PLoS One2025https://conductscience.org/library/papers/41411278PubMed
41148426CCL20 mediates the effect of cathepsin S on hepatocellular carcinoma development insights from Mendelian randomization and bioinformatics analysis.Discov Oncol2025https://conductscience.org/library/papers/41148426PubMed
41035085Critical analysis of the liver cancer policies and programs in China: implications for international liver cancer control.Glob Health Res Policy2025https://conductscience.org/library/papers/41035085PubMed
40735995Cancer Cell-Coated PLGA Nanoparticles Loaded with Sorafenib and Spions for Hepatocellular Carcinoma Theranostics.Curr Drug Deliv2026https://conductscience.org/library/papers/40735995PubMed
40670432Analysis of factors influencing tumor volume doubling time in hepatocellular carcinoma and its predictive value for progression-free survival.Sci Rep2025https://conductscience.org/library/papers/40670432PubMed
40523760Identification of prognosis-related key genes in hepatocellular carcinoma based on bioinformatics analysis.Zhong Nan Da Xue Xue Bao Yi Xue Ban2025https://conductscience.org/library/papers/40523760PubMed
40516009Single cell analysis and bioinformatics reveal pyroptosis mechanisms in hepatocellular carcinoma.Discov Oncol2025https://conductscience.org/library/papers/40516009PubMed
40507701Determinants of Health-Related Quality of Life After Transarterial Chemoembolization in Hepatocellular Carcinoma Patients: A Systematic Review.J Clin Med2025https://conductscience.org/library/papers/40507701PubMed
40504321Radiofrequency Ablation Technology in Liver Malignancies: A Systematic Review of Economic Evaluations.J Gastrointest Cancer2025https://conductscience.org/library/papers/40504321PubMed
40502525Multidisciplinary treatment strategies for the assessment of immune, coagulation, and biomarker responses after transarterial chemoembolization for hepatocellular carcinoma.World J Gastrointest Surg2025https://conductscience.org/library/papers/40502525PubMed
40188134Psychosocial factors associated with quality of life in cancer patients undergoing treatment: an umbrella review.Health Qual Life Outcomes2025https://conductscience.org/library/papers/40188134PubMed
39820759Exploring early postoperative core symptoms in Chinese patients with primary liver cancer: a cross-sectional and longitudinal network analysis.Support Care Cancer2025https://conductscience.org/library/papers/39820759PubMed
39609433A brain-to-liver signal mediates the inhibition of liver regeneration under chronic stress in mice.Nat Commun2024https://conductscience.org/library/papers/39609433PubMed
39598228The ncRNA-AURKA Interaction in Hepatocellular Carcinoma: Insights into Oncogenic Pathways, Therapeutic Opportunities, and Future Challenges.Life (Basel)2024https://conductscience.org/library/papers/39598228PubMed

See all 39 cited byDownload CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ALB213PubTator's text mininghttps://conductscience.org/library/genes/213NCBI Gene
ALPP250PubTator's text mininghttps://conductscience.org/library/genes/250NCBI Gene
CRP1401PubTator's text mininghttps://conductscience.org/library/genes/1401NCBI Gene
CXCL83576PubTator's text mininghttps://conductscience.org/library/genes/3576NCBI Gene
TENM110178PubTator's text mininghttps://conductscience.org/library/genes/10178NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35530735

GET https://conductscience.org/api/papers/v1/35530735/references?page=2